A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

260 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-14

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of intra-articular administration of PTP-001 (MOTYS) for the treatment of knee osteoarthritis.

The purpose of the trial is to evaluate the efficacy, safety, and tolerability of a single intra-articular injection of PTP-001 compared to placebo over a 52-week period in participants with radiographic and symptomatic knee OA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis

NCT05100225

Osteoarthritis, Knee

UNKNOWN PHASE2

A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

NCT04875754

Osteoarthritis, Knee

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Evaluating the Efficacy and Safety of Intra-articular Injection of HS-20116 in Patients With Knee Osteoarthritis

NCT07047196

Knee Osteoarthritis

COMPLETED PHASE3

Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis

NCT03727022

Knee Osteoarthritis

COMPLETED PHASE2

Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)

NCT02095548

Moderate to Severe Osteoarthritis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The participants will be randomized in a 1:1 ratio to receive one of either PTP-001 or placebo injection. Each participant will be administered a single dose of investigational product (IP) (active or placebo) on Day 1.

The trial will consist of a Screening period (up to 28 days prior to treatment), a treatment phase (1 day) and a follow-up phase (12 months following treatment). A total of at least 260 participants are planned to be randomized (130 participants/group).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

This is a double-blinded trial, in which neither participant nor investigator will know the content of the investigational product. Additionally, unblinded personnel that prepare the syringe and administer the injection must not be involved in any other operational aspects of the trial.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PTP-001 200 mg

A single intra-articular injection in the target knee of PTP-001 200 mg

Group Type EXPERIMENTAL

PTP-01

Intervention Type BIOLOGICAL

Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.

Placebo / saline vehicle

A single intra-articular injection in the target knee of 4 mL of placebo control (0.9% sodium chloride injection, USP)

Group Type PLACEBO_COMPARATOR

Placebo control / saline vehicle

Intervention Type OTHER

The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTP-01

Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.

Intervention Type BIOLOGICAL

Placebo control / saline vehicle

The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MOTYS™ allogeneic human placental tissue particulate Normal saline Physiological saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females aged 40 to 80 years.
2. Presenting with symptomatic knee OA with Kellgren-Lawrence (KL) radiographic classification of 2 or 3 (mild or moderate), as assessed by the central reading facility.
3. Primary source of pain throughout the body is due to OA in the target knee.
4. Target knee pain ≥ 20 and ≤ 40 out of 50 on the WOMAC® numerical rating scale (NRS) 3.1 pain questionnaire (sum of 5 questions) at Screening and Baseline.
5. Onset of symptomatic OA of the target knee was at least 6 months prior to Screening.
6. Insufficient, failed response, or intolerance to analgesics and / or non-steroidal anti-inflammatory drugs (NSAIDs), as reported by the participant.
7. If female, must meet all of the following:

1. Not breast feeding,
2. Not planning to become pregnant during the study,
3. Must abstain from ova / egg donation during the study,
4. If of childbearing potential, must have a negative pregnancy test result within 72 hours prior to receiving the intra-articular injection, and must commit to the use of a highly effective form of birth control for at least 90 days after the injection.
8. Willing to remain on the same oral "rescue" (as needed) analgesic as the only pharmacologic treatment for knee pain during the study.
9. Willing to abstain from taking any illicit or unauthorized medications for treatment of OA or any other concurrent condition during the study.
10. Willing to comply with post-injection restrictions.
11. Written informed consent is obtained from the participant.

Exclusion Criteria

1. Participant is non-ambulatory (unable to walk \> 50 feet / 15 meters without assistance).
2. Clinically severe obesity as defined by the National Institutes of Health (body mass index ≥ 40 kg/m2) at Screening and / or Baseline.
3. Contralateral (non-target) knee pain is ≥ 6 out of 50 on the WOMAC® NRS 3.1 pain questionnaire (sum of 5 questions) at Screening or at Baseline.
4. At Baseline, difference between the first and second WOMAC pain scores is ≥ 3 for the target knee.
5. Contralateral (non-target) knee pain is experienced for ≥ 14 days in the month.
6. Use of any analgesia during the washout period (5 half-lives) at Screening or Baseline.
7. Participation in any investigational study within 30 days (or 5 half-lives, whichever is longer) prior to Screening or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion.
8. Currently requires use of a lower extremity prosthesis and / or a structural knee brace (ie, a knee brace that contains hardware).
9. Clinically significant effusion of the target knee at either the Screening or Baseline visits as determined by physical examination (eg, ballotable patella or positive bulge sign).

Note: Participants presenting with effusion may be enrolled in the study after undergoing knee aspiration to remove excess fluid in the target joint.
10. Severe (excessive) malalignment of the tibial-femoral axis assessed radiographically (by previous X-ray, rather than that performed for Kellgren-Lawrence assessment).
11. Presence of active infection in the target knee or systemic infection requiring treatment within the 3 months prior to Screening.
12. Clinical diagnosis of inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, etc.) established by clinical history, examination, or serology.
13. Participant is receiving, has received, or plans to receive any of the following therapies:

1. Prior administration of hyaluronic acid, extended-release corticosteroid (eg, Zilretta®), platelet-rich plasma (PRP), or stem cell therapies by intra-articular injection(s) of the target knee within 6 months prior to Screening.
2. Prior administration of corticosteroid by intra-articular injection of the target knee within 3 months prior to Screening or into any other joint within 30 days prior to Screening.
3. Current chronic systemic use of corticosteroids in doses exceeding the equivalent of 10 mg prednisolone daily.
4. Treatment with any investigational therapy (drug, device, or biologic) within 3 months prior to Screening or is planned for the duration of the study.
5. Treatment with immunosuppressive medication (not including mild transient immunosuppressants such as corticosteroids) or chemotherapy within the past 5 years.
14. Chronic use of narcotics or alcohol abuse within the past 6 months prior to Screening.
15. Surgery to either knee (including arthroscopy) within 6 months prior to receiving the intra-articular injection or planned surgery of either knee within 6 months after the injection.
16. Participant previously underwent arthroplasty of the target knee.
17. Presence of joint instability or complaints of locking, intermittent limitation in range of motion, or loose body sensation, suggestive of internal derangement of the knee (either extremity).
18. Diagnosis of lower extremity gout or pseudo-gout in the past 6 months prior to Screening.
19. History of, or current manifestation of, osteonecrosis of either knee.
20. Significant acute (within the past 3 months) injury to the target knee.
21. History of receiving a solid organ or hematologic transplant.
22. History of malignancy, radiotherapy, or chemotherapy for malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin.
23. History of prior radiation therapy of the target knee.
24. History of autoimmune disease affecting the musculoskeletal system.
25. Known (documented) history of acquired immune deficiency syndrome or human immunodeficiency virus (HIV).
26. Any condition causing pain in or around the target knee (eg, radiating pain or pain in another region of the ipsilateral lower extremity) that may interfere with assessment(s) of the target knee. 27. Other chronic pain anywhere in the body that requires the chronic use of analgesic medications, such as knee OA of the contralateral (non-target) knee, fibromyalgia, tendonitis, plantar fasciitis, neuropathic pain, lower back pain, etc.

28\. Known presence of any concurrent medical condition (eg, hematologic renal, hepatic, cardiac, or coagulation abnormalities) that in the Investigator's judgment would interfere with the required study assessments and study participation.

29\. Participant is involved in litigation (eg, worker's compensation) for a medical condition or injury at any anatomical site.

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No